Skip to content

Boston Scientific presents multiple long-term data outcomes at NANS meeting

Boston Scientific Corporation recently featured clinical data at the North American Neuromodulation Society (NANS) annual meeting, held in Las Vegas, Nevada, on Jan. 22-25, 2026. A total of 17 abstracts, including seven oral presentations, from the chronic pain and deep brain stimulation portfolios

Boston Scientific presents multiple long-term data outcomes at NANS meeting
Published: | 1 min read

Boston Scientific Corporation recently featured clinical data at the North American Neuromodulation Society (NANS) annual meeting, held in Las Vegas, Nevada, on Jan. 22-25, 2026. A total of 17 abstracts, including seven oral presentations, from the chronic pain and deep brain stimulation portfolios were presented.

Key findings presented include:

  • Three-year positive outcomes from a multicenter global real-world study assessing patients using Fast-Acting Sub-perception Therapy (FAST), designed to provide paresthesia-free pain relief in minutes.
  • Three-year results from the global, prospective RELIEF registry highlight long-term outcomes of spinal cord stimulation (SCS) therapy across multiple indications in more than 500 patients.
  • Two-year results from the SOLIS (SCS as an Option for Chronic Low Back and/​or Leg Pain Instead of Surgery) randomised controlled trial for non-surgical back pain outcomes for patients using FAST Therapy.

“The data presented at this year’s NANS add to the growing body of evidence for our spinal cord stimulation therapies and underscore our category leadership in the pain space,” said Jim Cassidy, president, Neuromodulation, Boston Scientific. “By continuing to invest in long-term science and innovation, we’re helping physicians offer more personalised, proven treatment options for their patients.”

At the meeting, Boston Scientific is also showcasing the Intracept EDGE J Stylet, an instrument of the Intracept Intraosseous Nerve Ablation System. This latest advancement is designed to optimise access to the basivertebral nerve and streamline the treatment experience.

The Intracept procedure is the first U.S. FDA-cleared device-based therapy for vertebrogenic low back pain and has demonstrated improved function and long-term pain relief. Meeting attendees can explore the latest innovation at booth #131, where a hands-on simulator experience will be available.

For a complete list of Boston Scientific clinical and scientific data presentations at NANS 2026, please visit: NANS 2026 – Boston Scientific.

Sign up to our newsletter

The week's biggest stories from this industry, direct to your inbox.

Personal information

More in Medical Device Manufacturing

See all

More from Oliver Johnson

See all
Holistic scientific frameworks for real-world use

Holistic scientific frameworks for real-world use

/

From our partners

Sponsored content
Driving innovation in medical motion control

Driving innovation in medical motion control

Whether it’s the smooth articulation of a surgical robot, the precise positioning of an imaging system, or the reliable, repeatable movement inside a laboratory instrument, motion control plays a key role in modern medical devices. Despite this, however, it is often one of the most complex aspects o

/